-
Urology Jun 1981Two hundred patients treated with phenoxybenzamine for benign prostatic obstruction were reviewed. In 171 of these patients the treatment was given to relieve symptoms...
Two hundred patients treated with phenoxybenzamine for benign prostatic obstruction were reviewed. In 171 of these patients the treatment was given to relieve symptoms in patients not requiring operation, or in patients in whom operation was postponed. Eighty per cent of these patients derived benefit from the treatment, most commonly for the obstructive symptoms (78.7 per cent) but almost as often for nocturia (76 per cent). The treatment was also found to be useful in aiding catheter removal after an attack of acute retention, and in preventing recurrent attacks of acute retention. Side effects occurred in 30 per cent of patients, but necessitated cessation of treatment in only 10 per cent. They consisted of other alpha-blocking effects, and caused after stopping or reducing treatment.
Topics: Adult; Age Factors; Aged; Humans; Male; Middle Aged; Phenoxybenzamine; Physical Examination; Prostatic Hyperplasia; Recurrence; Urinary Bladder Neck Obstruction; Urinary Catheterization; Urination Disorders
PubMed: 6166111
DOI: 10.1016/0090-4295(81)90071-6 -
The Journal of Cardiovascular Surgery 1967
Topics: Animals; Blood Pressure; Dogs; Extracorporeal Circulation; Kidney; Phenoxybenzamine; Regional Blood Flow; Vascular Resistance
PubMed: 6021198
DOI: No ID Found -
European Urology 1998Once benign prostatic obstruction (BPO) is diagnosed, the urologist is confronted with an array of therapeutic modalities, from which he has to choose. The decision can... (Review)
Review
OBJECTIVE
Once benign prostatic obstruction (BPO) is diagnosed, the urologist is confronted with an array of therapeutic modalities, from which he has to choose. The decision can be based on the patient's desire, deobstructing efficacy, durability, cost and on the physician's experience as well as availability of modalities.
METHODS
A therapeutic spectrum is constructed for individualization of therapeutic options in evaluation of the relevant factors based on the published studies.
RESULTS
In treating BPO the surgical treatment (TURP, TUIP) is still the most reliable in experienced hands, and its cost-efficacy has to be weighed against durability. If LUTS without intravesical obstruction dominates, alpha-blocker or finasteride (prostates >40 g) are useful and more efficient than watchful waiting when symptom relief and uroflow improvement are outcome parameters. Interventional treatment modalities remain a moving target, since even high-energy TUMT does not overcome obstruction. Ablation techniques (Holmium laser, TEVAP) have not been used with regard to durability.
CONCLUSION
Picking an inappropriate modality or selecting the wrong patient may lead to a cascade of therapies. One can obtain a change in paradigms to measure the outcome putting emphasis on cost, need to retreat and, last but not least, quality of life.
Topics: Adrenergic alpha-Antagonists; Combined Modality Therapy; Costs and Cost Analysis; Enzyme Inhibitors; Finasteride; Humans; Male; Patient Satisfaction; Phenoxybenzamine; Prognosis; Prostatectomy; Prostatic Hyperplasia; Treatment Outcome
PubMed: 9705552
DOI: 10.1159/000052273 -
Bioscience Reports Apr 1989In isolated rat islets the alpha 2-adrenergic antagonist phenoxybenzamine was found to be only partially effective at relieving the inhibition of glucose-induced insulin...
In isolated rat islets the alpha 2-adrenergic antagonist phenoxybenzamine was found to be only partially effective at relieving the inhibition of glucose-induced insulin secretion mediated by noradrenaline. Further experiments revealed a direct inhibitory effect of phenoxybenzamine itself on the secretory response to glucose. At concentrations above 1 microM the antagonist inhibited insulin secretion in a dose-dependent manner, with greater than 50% inhibition at 50 microM. The inhibition of secretion developed rapidly in perifused islets, and was not altered when islets were also incubated with idazoxan or benextramine, suggesting that it did not reflect binding of phenoxybenzamine to the alpha 2-receptor. Paradoxically phenoxybenzamine significantly increased the basal secretion rate in the presence of 4 mM glucose. The results demonstrate that phenoxybenzamine can exert direct effects on insulin secretion which are unrelated to its alpha-antagonist properties.
Topics: Animals; Glucose; Insulin; Insulin Secretion; Islets of Langerhans; Male; Phenoxybenzamine; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha
PubMed: 2548636
DOI: 10.1007/BF01115999 -
Bioorganic & Medicinal Chemistry Letters Jul 2019Histone deacetylase (HDAC) inhibitors as an important epigenetic therapeutic strategy affect signaling networks and act synergistically with kinase inhibitors for the...
Histone deacetylase (HDAC) inhibitors as an important epigenetic therapeutic strategy affect signaling networks and act synergistically with kinase inhibitors for the treatment of cancer. Herein we presented a series of novel phenoxybenzamide analogues with inhibition of Raf and HDAC. Among them, compound 10e showed potent antiproliferative activities against Hepg2 and MDA-MB-468 in cellular assays. This work may lay the foundation for developing novel dual Raf/HDAC inhibitors as potential anticancer therapeutics.
Topics: Histone Deacetylase Inhibitors; Humans; Phenoxybenzamine; Structure-Activity Relationship
PubMed: 31053508
DOI: 10.1016/j.bmcl.2019.04.047 -
Japanese Heart Journal Mar 1979From 1971 to 1977, a total of 43 cases with ventricular septal defect associated with pulmonary hypertension (VSD + PH), ranging from 3 months to 6 years of age,...
From 1971 to 1977, a total of 43 cases with ventricular septal defect associated with pulmonary hypertension (VSD + PH), ranging from 3 months to 6 years of age, underwent VSD closure using cardiopulmonary bypass with a prophylactic dose of phenoxybenzamine (POB) 1 mg/Kg. Twenty of these cases are included in the present study of the effect of POB on pulmonary hypertension. The ratios of pulmonary to systemic arterial pressures (Pp/Ps) and vascular resistances (Rp/Rs) were measured before, immediately after and 1 month after VSD closure. In all cases, the Pp/Ps before VSD closure was larger than 0.75. Both Pp/Ps and Rp/Rs markedly decreased immediately after VSD closure but rose again 1 month thereafter. These results suggest the possibility of pulmonary vasodilating effect of POB, which could be potentially useful in relieving the right ventricular load in the early postoperative period. The over all mortality was 3 out of 43 cases including 2 late deaths.
Topics: Blood Pressure; Child; Child, Preschool; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Infant; Phenoxybenzamine; Postoperative Care; Postoperative Complications; Pulmonary Artery; Pulmonary Circulation; Vascular Resistance
PubMed: 449050
DOI: 10.1536/ihj.20.157 -
Urology Jun 1977
Topics: Humans; Phenoxybenzamine; Urinary Bladder, Neurogenic
PubMed: 883080
DOI: 10.1016/0090-4295(77)90332-6 -
Acta Europaea Fertilitatis 1986Phenoxybenzamine has been extremely effective in treating patients with vesical dysfunctions, its minimal side effects include anejaculation and delay and difficulty in...
Phenoxybenzamine has been extremely effective in treating patients with vesical dysfunctions, its minimal side effects include anejaculation and delay and difficulty in ejaculation. Fifteen men were treated with phenoxybenzamine (PBZ) for premature ejaculation. Eight patients reported a subjective improvement of the time from penetration to ejaculation. PBZ is a well tolerated drug. The only side effect of the treatment was dry ejaculation. The Authors suggest its use in selected patients.
Topics: Adult; Ejaculation; Humans; Male; Middle Aged; Penile Erection; Phenoxybenzamine; Receptors, Adrenergic, alpha
PubMed: 3014791
DOI: No ID Found -
Fertility and Sterility Oct 1984
Topics: Adult; Ejaculation; Female; Humans; Male; Middle Aged; Phenoxybenzamine; Sexual Dysfunction, Physiological
PubMed: 6541599
DOI: 10.1016/s0015-0282(16)48157-4 -
Biochemical Pharmacology May 1986In this study, we used phenoxybenzamine to label the alpha 1-adrenergic receptor of a smooth muscle cell line. Our results demonstrate a dose-dependent occupancy of...
In this study, we used phenoxybenzamine to label the alpha 1-adrenergic receptor of a smooth muscle cell line. Our results demonstrate a dose-dependent occupancy of alpha 1-adrenergic receptors by phenoxybenzamine determined by competition for the [3H]prazosin binding site. Following incorporation of [3H]phenoxybenzamine, partially purified membranes were solubilized and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions. Despite numerous Coomassie blue-stained bands, only three bands, Mr = 80,000 +/- 500, Mr = 33,000 +/- 2,000, and Mr = 21,000 +/- 400 (N = 4), were labeled with [3H]phenoxybenzamine as determined by autofluorography. Incorporation of [3H]phenoxybenzamine into the Mr = 80,000 band, but not the Mr = 33,000 and Mr = 21,000 bands, was affected by adrenergic agonists and antagonists in a manner consistent with an alpha 1-adrenergic interaction. Labeling of the Mr = 33,000 and Mr = 21,000 bands was partially blocked by phenoxybenzamine. We conclude that [3H]phenoxybenzamine can be used as an affinity probe for the alpha 1-adrenergic receptor and that the ligand binding site of the alpha 1-adrenergic receptor resides in a Mr = 80,000 protein.
Topics: Affinity Labels; Animals; Azides; Cells, Cultured; Cricetinae; Epinephrine; Male; Mesocricetus; Molecular Weight; Phenoxybenzamine; Prazosin; Receptors, Adrenergic, alpha; Stereoisomerism; Tritium; Vas Deferens
PubMed: 3011011
DOI: 10.1016/0006-2952(86)90320-5